Cargando…

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

Lung cancer, mostly nonsmall cell lung cancer, continues to be the leading cause of cancer-related death worldwide. With the development of tyrosine kinase inhibitors that selectively target lung cancer-related epidermal growth factor receptor mutations, management of advanced nonsmall cell lung can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Xinghua, Chen, Haiquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181629/ https://www.ncbi.nlm.nih.gov/pubmed/25285017 http://dx.doi.org/10.2147/OTT.S66502

Ejemplares similares

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
por: Kobayashi, Kunihiko, et al.
Publicado: (2013)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world
por: Shokoohi, Aria, et al.
Publicado: (2021)

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
por: Glatzer, Markus, et al.
Publicado: (2016)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
por: Walleser, Silke, et al.
Publicado: (2012)

Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy
por: Bala, Stalin, et al.
Publicado: (2016)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023)

Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis
por: Ma, Jie-Tao, et al.
Publicado: (2018)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer
por: Xu, Weiru, et al.
Publicado: (2014)

New developments in locally advanced nonsmall cell lung cancer
por: Huber, Rudolf M., et al.
Publicado: (2021)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer
por: Hu, Yanni, et al.
Publicado: (2012)

Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer
por: Lei, Weijie, et al.
Publicado: (2017)

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
por: Crinò, Lucio, et al.
Publicado: (2014)

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
por: Sebastian, Martin, et al.
Publicado: (2014)

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Mao, Chen, et al.
Publicado: (2015)

CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
por: Catalán, Rodrigo, et al.
Publicado: (2020)

Spontaneous regression of locally advanced nonsmall cell lung cancer: A case report
por: Ooi, Kiat Huat, et al.
Publicado: (2018)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer
por: Ni, Jun, et al.
Publicado: (2016)

The detection of primary and secondary EGFR mutations using droplet digital PCR in patients with nonsmall cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2018)

Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status
por: Yu, Xiaoqing, et al.
Publicado: (2019)

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers
por: Wang, Caolin, et al.
Publicado: (2018)

Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
por: Gong, Juejun, et al.
Publicado: (2021)

EGFR targeted therapy resistance: current status, challenges, and future outlook
por: Bivona, Trever G.
Publicado: (2020)

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs
por: Zhang, Yuan, et al.
Publicado: (2018)

Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip
por: Tan, Jianfeng, et al.
Publicado: (2022)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis
por: Su, Wenxia, et al.
Publicado: (2019)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018)

Id1 Promotes Tumor Cell Migration in Nonsmall Cell Lung Cancers
por: Bhattacharya, Raka, et al.
Publicado: (2010)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Prognostic Value of Fluoro-D-glucose Uptake of Primary Tumor and Metastatic Lesions in Advanced Nonsmall Cell Lung Cancer
por: Nguyen, Xuan Canh, et al.
Publicado: (2014)

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution
por: He, Xiaobo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kqptg6b64a19v6t993i3lk822o